MCID: DRG004
MIFTS: 31

Drug-Induced Mental Disorder malady

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Drug-Induced Mental Disorder

Aliases & Descriptions for Drug-Induced Mental Disorder:

Name: Drug-Induced Mental Disorder 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:1203
ICD9CM 35 292.8 292.89
UMLS 69 C0154325

Summaries for Drug-Induced Mental Disorder

MalaCards based summary : Drug-Induced Mental Disorder is related to polyneuropathy and antisocial personality disorder. An important gene associated with Drug-Induced Mental Disorder is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Serotonergic synapse and GPCRs, Other. The drugs Metformin and Aripiprazole have been mentioned in the context of this disorder. Related phenotypes are shRNA abundance <= 50% and behavior/neurological

Related Diseases for Drug-Induced Mental Disorder

Diseases related to Drug-Induced Mental Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 43)
id Related Disease Score Top Affiliating Genes
1 polyneuropathy 10.3 HTR1A HTR2A
2 antisocial personality disorder 10.3 HTR1A HTR2A
3 aryepiglottic fold cancer 10.3 HTR1A HTR2A
4 optic disk drusen 10.2 IDH1 IDH2
5 waardenburg's syndrome 10.2 DRD2 HTR1A HTR2A
6 enterovesical fistula 10.2 IDH1 IDH2
7 acrocallosal syndrome 10.2 IDH1 IDH2
8 postencephalitic parkinson disease 10.2 DRD2 HTR1A HTR2A
9 neurilemmoma 10.2 IDH1 IDH2
10 cecal benign neoplasm 10.1 DRD2 HTR1A HTR2A
11 testis refractory cancer 10.1 IDH1 IDH2
12 cytomegalic congenital adrenal hypoplasia 10.1 DRD2 HTR2A NDUFS4
13 cystinosis, nephropathic 10.1 IDH1 IDH2
14 small cell osteogenic sarcoma 10.1 IDH1 IDH2
15 hepatitis d 10.1 DRD2 HTR1A HTR2A
16 hereditary multiple exostoses 10.1 CNR1 DRD2 HTR2A
17 abnormal pupillary function 10.1 HTR1A HTR7
18 dry eye syndrome 10.1 HTR1A HTR2A HTR7
19 glycogen storage disease type 0 10.1 IDH1 IDH2
20 keratosis 10.1 HTR1A HTR2A HTR7
21 alzheimer disease 17 10.1 HTR1A HTR2A HTR7
22 angioma hereditary neurocutaneous 10.1 IDH1 IDH2
23 retinoblastoma 10.1 DRD2 HTR1A HTR2A
24 neuropathy, ataxia, and retinitis pigmentosa 10.1 IDH1 IDH2
25 chronic conjunctivitis 10.1 CNR1 DRD2 HTR1A HTR2A
26 benign epilepsy with centrotemporal spikes 10.1 CNR1 DRD2 HTR1A HTR2A
27 breast papillomatosis 10.0 IDH1 IDH2
28 prosopagnosia 10.0 IDH1 IDH2
29 indeterminate leprosy 10.0 HTR2A HTR7
30 rectosigmoid junction neoplasm 10.0 CNR1 DRD2 HTR7
31 hemochromatosis, type 2a 9.9 DRD2 NDUFS4 PINK1
32 microcephaly 13, primary, autosomal recessive 9.9 DRD2 HTR1A HTR2A HTR7
33 spinal cord astrocytoma 9.9 IDH1 IDH2
34 mixed lacrimal gland cancer 9.9 FOS HTR1A HTR7
35 autoimmune disease of endocrine system 9.8 CNR1 FOS HTR7
36 cervical carcinosarcoma 9.8 CNR1 FOS HTR7
37 preeclampsia/eclampsia 5 9.8 CNR1 DRD2 HTR1A HTR2A HTR7
38 ellis-van creveld syndrome 9.8 DRD2 FOS HTR1A HTR2A
39 siberian tick typhus 9.8 CNR1 FOS HTR1A HTR7
40 schizophrenia 9.7 CNR1 DRD2 HTR1A HTR2A HTR7 NDUFS4
41 personality disorder 9.4 ADAMTS2 CNR1 DRD2 FOS HTR1A HTR2A
42 allergic hypersensitivity disease 8.1 ADAMTS2 CNR1 DRD2 DUSP26 EPHA5 FOS
43 vascular cancer 8.1 ADAMTS2 CNR1 DRD2 DUSP26 EPHA5 FOS

Graphical network of the top 20 diseases related to Drug-Induced Mental Disorder:



Diseases related to Drug-Induced Mental Disorder

Symptoms & Phenotypes for Drug-Induced Mental Disorder

GenomeRNAi Phenotypes related to Drug-Induced Mental Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.36 HTR1A HTR2A IDH2 NDUFS4 PINK1 TCOF1

MGI Mouse Phenotypes related to Drug-Induced Mental Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 PHB2 PINK1 CNR1 DRD2 FOS HTR1A
2 growth/size/body region MP:0005378 9.96 ADAMTS2 CNR1 DRD2 DUSP26 FOS IDH1
3 integument MP:0010771 9.7 ADAMTS2 CNR1 DRD2 FOS HTR7 NDUFS4
4 nervous system MP:0003631 9.61 CNR1 DRD2 EPHA5 FOS HTR1A HTR7
5 skeleton MP:0005390 9.32 IDH1 IDH2 NDUFS4 PINK1 TCOF1 ADAMTS2

Drugs & Therapeutics for Drug-Induced Mental Disorder

Drugs for Drug-Induced Mental Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 176)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
4
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1 106266-06-2 5073
5
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1 132539-06-1 4585
6
Ziprasidone Approved Phase 4 146939-27-7 60854
7
Lorazepam Approved Phase 4 846-49-1 3958
8
Topiramate Approved Phase 4 97240-79-4 5284627
9
Clozapine Approved Phase 4 5786-21-0 2818
10
Acetaminophen Approved Phase 4 103-90-2 1983
11
Ethanol Approved Phase 4 64-17-5 702
12
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
13
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1 2078-54-8 4943
14
Memantine Approved, Investigational Phase 4 19982-08-2 4054
15
Asenapine Approved Phase 4,Phase 3 85650-56-2, 65576-45-6 3001386
16 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
18 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
19 Quetiapine Fumarate Phase 4,Phase 2,Phase 3,Phase 1 111974-72-2
20 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Hypoglycemic Agents Phase 4,Phase 3
22 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
25
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
26 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Serotonin Antagonists Phase 4,Phase 2,Phase 1
28 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
29 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 1
34 Anti-Anxiety Agents Phase 4,Phase 1
35 Anticonvulsants Phase 4,Phase 2,Phase 1
36 Anti-Obesity Agents Phase 4
37 GABA Agents Phase 4,Phase 1
38 GABA Modulators Phase 4,Phase 1
39 Hypnotics and Sedatives Phase 4,Phase 1
40 Neuroprotective Agents Phase 4,Phase 2
41 Protective Agents Phase 4,Phase 2
42 Analgesics Phase 4,Phase 1
43 Analgesics, Non-Narcotic Phase 4,Phase 1
44 Antipyretics Phase 4
45 Liver Extracts Phase 4
46 Adrenergic Agents Phase 4,Phase 2,Phase 1
47 Adrenergic Agonists Phase 4,Phase 1
48 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 1
49 Adrenergic alpha-Agonists Phase 4,Phase 1
50 Anesthetics Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show all 48)
id Name Status NCT ID Phase
1 Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4
2 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4
3 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4
4 Antipsychotics and Gene Expression in Soft Tissues Completed NCT01185743 Phase 4
5 Characterizing and Predicting Drug Effects on Cognition Completed NCT01889602 Phase 4
6 Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders Completed NCT00845988 Phase 4
7 An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia Completed NCT00269919 Phase 4
8 Hepatic Function in Alcoholics Following 5 Days of Acetaminophen Dosing Completed NCT00427206 Phase 4
9 Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics Completed NCT00458211 Phase 4
10 Hepatic Function During and Following Three Days of Acetaminophen Dosing in Alcoholics Completed NCT00402571 Phase 4
11 Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia Completed NCT00328367 Phase 4
12 The Neural Mechanisms of Anesthesia and Human Consciousness Completed NCT01889004 Phase 4
13 Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease Completed NCT01108029 Phase 4
14 The Effect of Paliperidone Palmitate in Schizophrenia Completed NCT01860781 Phase 4
15 Asenapine in the Treatment of Older Adults With Bipolar Disorder Completed NCT01460290 Phase 4
16 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain Terminated NCT01844700 Phase 4
17 A Study of Olanzapine in Patients With Schizophrenia Completed NCT00970281 Phase 3
18 Olanzapine Treatment of Patients With Bipolar I Disorder Completed NCT00510146 Phase 3
19 Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue Completed NCT01794429 Phase 3
20 Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125) Completed NCT01142596 Phase 3
21 Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder Completed NCT00129220 Phase 3
22 A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes Completed NCT01725308 Phase 2, Phase 3
23 Is MS14 Helpful in Schizophrenia? Unknown status NCT01083381 Phase 2
24 Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia Completed NCT00175955 Phase 2
25 An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia Completed NCT00257023 Phase 2
26 A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia Completed NCT01606254 Phase 2
27 Clinical Studies on the Therapeutic Effects of Mirtazapine on Drug-craving in Cocaine Addicts. Completed NCT01949571 Phase 2
28 Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628) Terminated NCT00686699 Phase 2
29 Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145) Terminated NCT00693472 Phase 2
30 Effect of Affective Content on Drug Induced Amnesia of Episodic Memory Completed NCT00142493 Phase 1
31 Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1 Completed NCT00218530 Phase 1
32 BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006) Completed NCT00887601 Phase 1
33 Movement Disorders Caused by Antipsychotic Drugs in Older Patients Completed NCT00255879 Phase 1
34 Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics Unknown status NCT02366897
35 Vitamin D, SSRIs and the Musculoskeletal System Unknown status NCT01932931
36 Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease Completed NCT00004826
37 Effects of Drugs on Cerebral Blood Flow in Patients With Mood Disorders Completed NCT00001478
38 Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers Completed NCT01931059
39 Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment Completed NCT00809731
40 Antipsychotic Medication Extended Dosing Study Completed NCT00431574
41 Cognitive Assessment Battery (CAB) Beta Study Completed NCT01290861
42 Switching From Consta® to Sustenna® in Patients With Schizophrenia Completed NCT01698216
43 Risk of Acute Liver Injury in Users of Antimicrobials Completed NCT01434173
44 The Effects of Expectation on Natural and Drug -Induced Rewards Recruiting NCT01036230
45 Botulinum Toxin for the Treatment of Involuntary Movement Disorders Recruiting NCT00001208
46 Providing "Good Sleep" for ICU Sedation Active, not recruiting NCT01342328
47 Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies Not yet recruiting NCT02893371
48 Unique Brainstem Biomarkers of Early Parkinson's Disease Terminated NCT02761707

Search NIH Clinical Center for Drug-Induced Mental Disorder

Genetic Tests for Drug-Induced Mental Disorder

Anatomical Context for Drug-Induced Mental Disorder

Publications for Drug-Induced Mental Disorder

Variations for Drug-Induced Mental Disorder

Expression for Drug-Induced Mental Disorder

Search GEO for disease gene expression data for Drug-Induced Mental Disorder.

Pathways for Drug-Induced Mental Disorder

GO Terms for Drug-Induced Mental Disorder

Cellular components related to Drug-Induced Mental Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.02 CNR1 DRD2 EPHA5 HTR2A PINK1

Biological processes related to Drug-Induced Mental Disorder according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.99 CNR1 DRD2 HTR1A HTR2A HTR7 LHB
2 mitochondrion organization GO:0007005 9.65 IDH2 PHB2 PINK1
3 response to light stimulus GO:0009416 9.59 DRD2 FOS
4 regulation of dopamine secretion GO:0014059 9.58 DRD2 HTR2A
5 temperature homeostasis GO:0001659 9.58 DRD2 HTR2A
6 behavioral response to cocaine GO:0048148 9.57 DRD2 HTR2A
7 smooth muscle contraction GO:0006939 9.56 HTR2A HTR7
8 2-oxoglutarate metabolic process GO:0006103 9.55 IDH1 IDH2
9 vasoconstriction GO:0042310 9.54 HTR1A HTR7
10 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.52 DRD2 HTR2A
11 regulation of synaptic transmission, GABAergic GO:0032228 9.49 CNR1 DRD2
12 sleep GO:0030431 9.46 FOS HTR2A
13 behavior GO:0007610 9.43 HTR1A HTR2A
14 regulation of behavior GO:0050795 9.4 HTR1A HTR2A
15 serotonin receptor signaling pathway GO:0007210 9.37 HTR1A HTR2A
16 regulation of hormone secretion GO:0046883 9.32 HTR1A HTR2A
17 isocitrate metabolic process GO:0006102 9.26 IDH1 IDH2
18 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.16 HTR1A HTR7
19 negative regulation of dopamine secretion GO:0033602 8.96 CNR1 DRD2
20 glyoxylate cycle GO:0006097 8.62 IDH1 IDH2

Molecular functions related to Drug-Induced Mental Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.71 CNR1 DRD2 HTR1A HTR2A
2 drug binding GO:0008144 9.54 CNR1 DRD2 HTR2A
3 G-protein coupled serotonin receptor activity GO:0004993 9.5 HTR1A HTR2A HTR7
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.26 IDH1 IDH2
5 isocitrate dehydrogenase activity GO:0004448 9.16 IDH1 IDH2
6 neurotransmitter receptor activity GO:0030594 9.13 HTR1A HTR2A HTR7
7 serotonin binding GO:0051378 8.8 HTR1A HTR2A HTR7

Sources for Drug-Induced Mental Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....